Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...

Novo Nordisk partners with U.S. biotech Septerna in a $2.2 billion deal to develop oral small molecule drugs for obesity and ...

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...

With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...

Improvements with GLP-1 RAs in psoriasis and other chronic skin diseases point to their increased use in dermatology and a ...

A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement ...

Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.

As medications become increasingly popular to support weight loss, not all of them are approved by the U.S. Food and Drug ...

In the first head-to-head trial of its kind, people with obesity who took tirzepatide (sold under the brand names Mounjaro ...

While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

They are the two drugs of the moment, the weight loss products promising a miraculous solution to obesity and—in data ...